Homoharringtonine Combined with Cladribine and Aclarubicin (HCA) in Acute Myeloid Leukemia: A New Regimen of Conventional Drugs and Its Mechanism

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2022 Jul 25

PMID 35873796

Authors

Fenglin Wang

Min Xie

Pan Chen

Dan Wang

Minghua Yang

Affiliations

Soon will be listed here.

Abstract

Objective: The prognosis of children with refractory acute myeloid leukemia (AML) is poor. Complete remission (CR) is not always achieved with current salvage chemotherapy regimens before transplantation, and some patients have no chance of transplantation. Here, we aimed to describe a new regimen of conventional chemotherapy drugs (homoharringtonine, cladribine , and aclarubicin (HCA)) for refractory AML and its mechanism in vitro.

Methods: We retrospectively collected the clinical data of 5 children with primary refractory AML using HCA as reinduction chemotherapy, and CR rates, adverse reactions, and disease-free survival (DFS) were analyzed. The effects of homoharringtonine, cladribine, and aclarubicin alone or in combination on the proliferation of HL60 and THP1 cells were analyzed by CCK-8 assay. Furthermore, CCK-8 was used to determine the effects of HCA, alone or in combination with apoptosis inhibitors, necroptosis inhibitors, ferroptosis inhibitors, or autophagy inhibitors, on the proliferation of HL60 and THP1 cells and to screen for possible HCA-mediated death pathways in AML cells. The pathway of HCA-mediated AML cell death was further verified by Hoechst/PI staining, flow cytometry, and Western blotting.

Results: After 2 cycles of conventional chemotherapy, none of the 5 children with AML achieved CR and were then treated with the HCA regimen for two cycles, 4 of 5 achieved CR, and another child achieved CR with incomplete hematological recovery (CRi). After CR, 3 children underwent hematopoietic stem cell transplantation (HSCT), and only 2 of them received consolidation therapy. As of the last follow-up, all 5 patients had been in DFS for a range of 23 to 28 months. The inhibition rate of homoharringtonine, cladribine, and aclarubicin in combination on HL60 and THP1 cells was significantly greater than that of a single drug or a combination of two drugs. We found that inhibitors of apoptosis and necroptosis were able to inhibit HCA-mediated cell death but not ferroptosis or autophagy inhibitors. Compared with the control group, the number of apoptotic cells in the HCA group was significantly increased and could be reduced by an apoptosis inhibitor. Western blot results showed that PARP, caspase-3, and caspase-8 proteins were activated and cleaved in the HCA group, the expression of Bax was upregulated and that of Bcl-2 was downregulated. The expression of apoptosis-related proteins could be reversed by apoptosis inhibition. Compared with the control group, the expression levels of the necroptosis-related proteins RIP1, RIP3, and MLKL were downregulated in the HCA group but were not phosphorylated. The necroptosis inhibitor increased the expression of RIP1 but caused no significant changes in RIP3 and MLKL, and none were phosphorylated.

Conclusions: HCA, as a new regimen of conventional drugs, was a safe and efficacious reinduction salvage strategy in children with refractory AML before HSCT. HCA exhibits the synergistic growth inhibition of AML cells and induces cell death mainly through apoptosis.

Citing Articles

Rethinking Biosynthesis of Aclacinomycin A.

Xu Z, Tian P Molecules. 2023; 28(6).

PMID: 36985733 PMC: 10054333. DOI: 10.3390/molecules28062761.

References

Zhang N, Shao J, Li H, Yang J, Chen K, Zhu J . Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation. World J Pediatr. 2019; 16(2):152-158. DOI: 10.1007/s12519-019-00321-8. View

Su X, Yao J, Zhang G, He Y, Wei J, Ma Q . [Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors]. Zhonghua Xue Ye Xue Za Zhi. 2018; 38(12):1024-1030. PMC: 7342196. DOI: 10.3760/cma.j.issn.0253-2727.2017.12.004. View

Chen X, Ruan M, Liu F, Liu T, Chen X, Guo Y . [Clinical outcome of CAG regimen in 26 children with aucte myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020; 40(7):594-596. PMC: 7364898. DOI: 10.3760/cma.j.issn.0253-2727.2017.07.011. View

Xie M, Jiang Q, Li L, Zhu J, Zhu L, Zhou D . HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants. PLoS One. 2016; 11(10):e0164238. PMC: 5051946. DOI: 10.1371/journal.pone.0164238. View

Zhang J, Li L, Liu W, Jin Y, Zhao M, Zhou Y . Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia. Clin Transl Oncol. 2020; 23(1):48-57. DOI: 10.1007/s12094-020-02383-x. View

Wang L, Du F, Wang X . TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008; 133(4):693-703. DOI: 10.1016/j.cell.2008.03.036. View

Shen J, Yang H, Ni W, Qian W . [Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012; 41(5):485-90. View

Fuchs Y, Steller H . Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 2015; 16(6):329-44. PMC: 4511109. DOI: 10.1038/nrm3999. View

Chen J, Mu Q, Li X, Yin X, Yu M, Jin J . Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells. Oncotarget. 2017; 8(25):40318-40326. PMC: 5522237. DOI: 10.18632/oncotarget.16956. View

10.

Ma X, Wang J, Zhang W, Chen Y, Cao X, He A . [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015; 23(2):369-74. DOI: 10.7534/j.issn.1009-2137.2015.02.014. View

11.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

12.

Xu G, Mao L, Liu H, Yang M, Jin J, Qian W . Sorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literature. Int J Clin Exp Med. 2016; 8(11):19891-4. PMC: 4723746. View

13.

Wu W, Liu P, Li J . Necroptosis: an emerging form of programmed cell death. Crit Rev Oncol Hematol. 2011; 82(3):249-58. DOI: 10.1016/j.critrevonc.2011.08.004. View

14.

Long J, Ryan K . New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene. 2012; 31(49):5045-60. DOI: 10.1038/onc.2012.7. View

15.

Dondelinger Y, Aguileta M, Goossens V, Dubuisson C, Grootjans S, Dejardin E . RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 2013; 20(10):1381-92. PMC: 3770330. DOI: 10.1038/cdd.2013.94. View

16.

Gieseler F, Bauer E, Nuessler V, Clark M, Valsamas S . Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage. Leukemia. 1999; 13(11):1859-63. DOI: 10.1038/sj.leu.2401570. View

17.

Juliusson G, Hoglund M, Karlsson K, Lofgren C, Mollgard L, Paul C . Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol. 2003; 123(5):810-8. DOI: 10.1046/j.1365-2141.2003.04702.x. View

18.

Kantarjian H, OBrien S, Jabbour E, Barnes G, Pathak A, Cortes J . Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2014; 15(1):13-21. DOI: 10.1016/j.clml.2014.09.011. View

19.

Fan C, Yu W, Mai W, Meng H, Qian W, Tong H . [Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2016; 37(2):100-4. PMC: 7348192. DOI: 10.3760/cma.j.issn.0253-2727.2016.02.003. View

20.

Iihoshi H, Ishihara T, Kuroda S, Ishihara N, Saitoh H . Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017; 277:109-114. DOI: 10.1016/j.toxlet.2017.06.006. View